Federated Hermes Inc. Buys Shares of 284,576 Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Key Points

• Federated Hermes Inc. has acquired a new position in Neumora Therapeutics by purchasing 284,576 shares during the first quarter, valued at approximately $285,000.
• Neumora Therapeutics stock has recently seen a significant drop of 11.5%, trading at $1.46 with a market cap of $236.16 million.
• Research firms have issued mixed ratings on Neumora stock, with an average rating of "Hold" and a target price of $7.14, while two firms rated it as a buy.

Federated Hermes Inc. bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 284,576 shares of the company's stock, valued at approximately $285,000. Federated Hermes Inc. owned 0.18% of Neumora Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics in the 4th quarter valued at $117,000. Wells Fargo & Company MN lifted its holdings in Neumora Therapeutics by 23.0% during the 4th quarter. Wells Fargo & Company MN now owns 70,653 shares of the company's stock valued at $749,000 after purchasing an additional 13,196 shares during the last quarter. Numerai GP LLC lifted its holdings in Neumora Therapeutics by 46.7% during the 4th quarter. Numerai GP LLC now owns 51,696 shares of the company's stock valued at $548,000 after purchasing an additional 16,457 shares during the last quarter. Rafferty Asset Management LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $185,000. Finally, BNP Paribas Financial Markets bought a new stake in Neumora Therapeutics during the fourth quarter worth about $221,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Trading Up 4.0%

NMRA traded up $0.06 during trading on Wednesday, reaching $1.56. 483,868 shares of the company's stock were exchanged, compared to its average volume of 2,105,663. The company's fifty day moving average price is $1.27 and its 200-day moving average price is $1.17. The firm has a market capitalization of $252.64 million, a PE ratio of -0.99 and a beta of 2.91. Neumora Therapeutics, Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $17.19. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.54 and a current ratio of 10.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05. As a group, equities analysts forecast that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NMRA shares. Mizuho lifted their target price on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $7.14.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.